AlloVir

Allo Vir

Biotechnology, 1100 Winter St, Waltham, Massachusetts, 02451, United States, 51-200 Employees

allovir.com

  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is ALLOVIR

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-asso...

Read More

map
  • 1100 Winter St, Waltham, Massachusetts, 02451, United States Headquarters: 1100 Winter St, Waltham, Massachusetts, 02451, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • Diana Brainard CEO:   Diana Brainard

industries-icon Industry: Biotechnology

SIC SIC Code: 2836

checked-icon Does something look wrong? Fix it. | View contact records from ALLOVIR

AlloVir Org Chart and Mapping

Diana Brainard

Chief Executive Officer

Employees

William Wheeler

Senior Vice President, Corporate Law

Sama Adnan

Medical Director, Medical Affairs

Rachel Lewis

Executive Assistant to the General Counsel

Lynn Mason

Vice President, Clinical Operations and Data Management

Jamie Bol

Quality Control Co-Op

Sarah Mahoney

Senior Manager, HR Business Partner

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AlloVir

Answer: AlloVir's headquarters are located at 1100 Winter St, Waltham, Massachusetts, 02451, United States

Answer: AlloVir's phone number is 61********

Answer: AlloVir's official website is https://allovir.com

Answer: AlloVir's revenue is $25 Million to $50 Million

Answer: AlloVir's SIC: 2836

Answer: AlloVir has 51-200 employees

Answer: AlloVir is in Biotechnology

Answer: AlloVir contact info: Phone number: 61******** Website: https://allovir.com

Answer: AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The companys technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirs technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access